COHANCE LIFESCIENCES SHARE PRICE

Dividend yield: Stock traders can use it differently to distinguish between the probability & possibility of making money

Dividend yield is not just an investor’s tool. At certain points in the market, it becomes just as relevant – sometimes even more so – for traders. Yes, traders. Now, why would dividend yield, of all things, act like a support line? The explanation lies in market memory and psychology. Around a certain level of dividend yield, value-oriented funds begin to step in because the price suddenly offers the comfort of an income stock. Momentum traders see valuation support and a floor building underneath the price. Options desks recalibrate, as downside looks limited and covered calls turn attractive. Each group is reacting to its own cues, but collectively they create the reflexive bounce that turns weakness into opportunity for traders.

PSU stocks: Time to relook? But don’t use the 2023 lens; choose the business. 57 PSU stocks, some good, some not so good

A bull run from June 2023 to June 2024, and then a bear run for a year. PSU stocks now seem at a stage where it is probably time to look at them again. For those who have not noticed, some of these stocks have seen higher-than-average volumes. Also a sort of outperformance in the bearish phase where they did not decline like other stocks in the market. They are not in the news any more; nor are many talking about them on TV. All signs suggesting it might probably be time to look at them again. But this time do it from a very different perspective – and not just because they are PSU. What matters is the category of business they fall into.

For wealth creation, focus on ‘Irrespective of & Despite Trump’: 7 mid-caps from different sectors with upside potential of up to 42%

Friday evening. We are not using the exact words, but the essence of what President Trump said was: India and Russia have fallen into China’s hands. Saturday evening. A 180-degree turn. I have a great relationship with PM Modi and I am only upset because India is buying too much Russian oil, Trump said. So, if you had bearish thoughts on Friday, Saturday would have seen you thinking bullish. It is Sunday and one does not quite know what to expect today. We are dealing with a president whose statements seem to depend on which side of the bed he got up from. The difference is that this time we have an Indian reaction appreciating the positive statements. So, be hopeful but cautious. In this administration, nothing positive is done till it is done.

Auto ancillaries: As dust of EV hype settles, time to bet on select companies? 7 auto ancillary stocks with upside potential of 3 to 30%

One sector that has been out of the news but may make a comeback both to the headlines and the narrative is the auto ancillary sector. Before you go further, it is important to understand that these companies – which could create wealth – fall into four different categories. First, companies that were quick to understand and start work on their EV transformation years back. Second, those which were late to start because their OEM itself was not clear of its EV plans. Third, companies which did not anticipate the speed at which the transition to EV would come. And fourth, those that cannot make the transition because their products are not required in EVs. There is a sub category in this fourth segment: Companies that are making adjustments to stay relevant in the EV space.

Stock picks of the week: 6 stocks with consistent score improvement and return potential of up to 35% in 1 year

For the next few months, before you take any buy-sell decision on the stock market, ask yourself this question. How is the Nifty’s movement impacting the bottom line of a company whose stock you are planning to buy-sell? The answer will help you avoid making wrong decisions. Now, why is there a high probability of making a wrong decision? Simple: News flows and statements from the US administration will create confusion in the short term. So, check out the stock you are targeting carefully.

Silent and long-term winners of GST rationalisation: 17 stocks from different sectors which fit the bill

In the last few days, a simple trade has been taking place on the street. The government cuts the GST rate on a product, price falls, and households should buy more of it. So, stocks from FMCG and some other sectors have done well. But India’s experience over the last two decades tells a subtler story: Because a family saves on tax in one corner of its consumption basket, it doesn’t mean it will spend more in that same corner. Just to put this in perspective: If one is saving money on buying a soap, that saving will not go into buying additional soap. It might go into buying anything else. What is that something else? It may even be a product that has not seen any GST cut. The fact is that there are many stocks that are silent and long-term winners of the GST rate rationalisation.

Zydus Lifesciences shares in focus on licensing deal with Synthon for generic ZEPOSIA in US market

Zydus Lifesciences signed an exclusive licensing and supply deal with Netherlands-based Synthon BV to commercialize generic Ozanimod Capsules (ZEPOSIA) in the U.S., used for multiple sclerosis treatment. Synthon, one of the first filers, has FDA tentative approval, qualifying for a 180-day exclusivity period. Zydus will handle commercialization while Synthon oversees manufacturing and supply.

Stocks in news: Zydus Life, NTPC, HDFC Life, Varun Beverages, TVS Motor

Indian markets closed marginally higher, buoyed by GST reforms signaling a significant tax overhaul. Zydus Lifesciences will introduce a generic multiple sclerosis drug in the US, while NTPC permanently discontinues operations at its Tanda thermal project. Varun Beverages will manufacture visi-coolers through a joint venture, and TVS Motor launched the NTORQ 150 scooter.

These large- and mid-cap stocks can give more than 28 % return in 1 year, according to analysts

The way the market reacted to the GST rate rationalisation clearly shows that “sell-on-news mode” is still active. Now there are two reasons why the market has been in this particular mode. First: Some risks are still on the table (the India-US tariff tiff). The reason why we consider this a risk is that the 50% tariff cannot continue for long. Either it has to be settled, or it will escalate, with more goods being impacted, or even higher tariffs. History suggests that usually such wars don't start easily. But once they do, ego is the biggest hurdle to a solution. So, unless this is resolved by year-end, it will become an even bigger issue. The second reason: Valuations. However, GST brings some hope. We may see better top and bottom lines in some segments.

Zydus ties up with Synthon BV for multiple sclerosis drug launch in US

Zydus Lifesciences will launch a generic drug for multiple sclerosis in the United States. This is through a partnership with Synthon BV. Their subsidiary, Zydus Lifesciences Global FZE, has an agreement with Synthon. Synthon will handle regulatory approval and manufacturing. Zydus will manage the commercialization in the US. The market for this drug is estimated at USD 637 million.

Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus

Stock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company analyses, the report also collates analysts’ forecasts and trend analysis for each component. An average score in Stock Reports Plus is calculated by undertaking quantitative analysis of five key investment tools – earnings, fundamentals, relative valuation, risk, and price momentum.

These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analysts

In the last three trading sessions, the one thing clearly favouring the bulls was market breadth, especially in the mid-cap segment. A part of this optimism stems from the street’s expectation that the GST rate rationalisation will be implemented soon. Now, given that it may be implemented as soon as September 22, it probably takes away the fear that this festive season will suffer due to delayed purchases. So, in all probability, some select consumer stocks will get more attention in the coming days.

Cyclically negative, structurally positive: Will cement be a surprise winner? 9 cement stocks with an upside potential of up to 27%

In some sectors, it is better to own a basket of shares rather than have exposure to a single stock. Reason: When a sector goes through a phase of restructuring and consolidation, the chances are high that a set of winners will emerge. But it is tough to figure out which the winners will be. So, buy a basket. Also, unlike in the past when buying a basket of stocks was a cumbersome process, today it is just a click away. Now, why cement? Because it might be a surprise winner. What makes that sector a surprise winner? When fundamentals are changing, but scepticism levels are still high. Cement is a sector which has probably seen the maximum mergers and acquisition in the last three years and that suggests there has been a change in the operating matrix.

Time to think beyond correction & volatility? 7 small-caps from different sectors with upside potential of 13% to 50%

We are in turbulent and confused times, at least where the market is concerned. Sentiment on the street swings with each statement by an Indian minister or a US official, or President Trump himself. One way to deal with this is to sit it out. But if you are a smart investor with a long-term perspective you will be wondering whether this is the opportunity you have been waiting for. You may also be wondering whether, after an extended correction, small-cap stocks are at a stage where you should start looking at them? Perhaps. But you need to be smart about picking the right stocks.

These 9 banking stocks can give up to 32% returns in 1 year, according to analysts

When it comes to banking sector stocks, learn to deal with two opposite views on the street. Over the next few months, you will hear news of how bank margins have come under pressure. Ignore those headlines, Why? The fact is that, whenever the interest rate cycle turns down, there is a phase when banks see some margin compression. So it is a cyclical phenomenon, and does not change the macro story about why banks should be a part of your portfolio. And the macro story is that banks are the best play when it comes to the growth of the Indian economy.

Zydus launches VaxiFluTM trivalent influenza vaccine for flu protection in India

Zydus Lifesciences has introduced VaxiFlu, a trivalent influenza vaccine, in India. This vaccine aligns with WHO guidelines. It is for individuals aged six months and above. The vaccine contains updated strains for optimal protection. Flu remains a global health concern. It causes millions of severe illnesses and respiratory deaths annually. VaxiFlu aims to reduce vaccine-preventable diseases, especially in high-risk groups.

Time to look again, but make a distinction: 11 FMCG stocks which can give from just 1% to 22% returns in 1 year

It is after quite some time that FMCG stocks are in greenish territory. This is not only because they are seen as defensive stocks during a correction, but also because some green shoots are visible in terms of their real business thanks to the good monsoon this year. Adding to the positive bias is the GST rate rationalisation that is likely to happen soon. But that is where one needs to be more cautious. In terms of the GST rate move, don’t paint every FMCG stock with the same brush.

Anlon Healthcare IPO GMP: Will healthy subscription lead to a strong listing tomorrow?

Anlon Healthcare, a Gujarat-based API and pharma intermediates manufacturer, will debut on the stock exchanges on Wednesday after its Rs 121 crore IPO was subscribed nearly 7 times. Despite strong fundamentals and capacity expansion plans, the grey market premium suggests muted listing gains. Analysts remain optimistic about its long-term growth potential amid rising demand and the “China + 1” supply shift.

9 stocks to trade ex-dividend on Monday. Last chance to buy for eligibility

Investors eyeing dividend payouts should note that today is the ex-dividend date for nine companies, including Alivus Life Sciences with a Rs 5 per share dividend. Other notable companies like Triveni Engineering and Triveni Turbine are also offering dividends. To be eligible for these payouts, investors must hold the stocks before today's trading close.

F&O Radar| Deploy Broken Wing in Zydus Lifesciences to play bullish momentum for gains

Zydus Lifesciences shares show bullish momentum, forming a weekly Inverted Head and Shoulders pattern with a breakout above Rs 1,050. Traders can consider deploying a Broken Wing strategy to capitalise on potential short-term gains, supported by rising RSI, strong EMAs, and key derivatives support and resistance

Stocks to buy in 2025 for long term: Cohance Lifesciences, Divi’s Lab among 5 stocks that could give 10-30% return

Eris Lifesciences' unit gets Brazil health regulator nod

Eris Lifesciences announced that its Ahmedabad manufacturing facility secured approval from ANVISA, Brazil's health regulatory agency, following a successful inspection in May 2025. This clearance allows the Indian drugmaker to enter the Brazilian pharmaceutical market, the largest in South America. The company's shares saw a slight increase of 0.2 percent, trading at Rs 1,772.50 on the BSE following the announcement.

Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendation

Cohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing strong growth prospects in India’s CRDMO sector. The brokerage sees a high-teen revenue CAGR, led by China+1 diversification, pipeline visibility, and demand for diabetes and weight-loss therapies.